Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
J&J's nipocalimab granted FDA breakthrough designation for Sjögren's disease
J&J's nipocalimab granted breakthrough therapy designation by FDA for treating moderate-to-severe Sjögren’s disease, supported by positive DAHLIAS study results showing significant improvement in ClinESSDAI score at 24 weeks.
US FDA grants breakthrough therapy designation to Johnson & Johnson's nipocalimab to treat moderate-to-severe Sjögren's disease
Johnson & Johnson announced FDA's Breakthrough Therapy designation for nipocalimab in treating moderate-to-severe Sjögren's disease, a chronic autoantibody disease with no advanced treatments. Nipocalimab is the first FcRn blocker to show positive results in a phase 2 study for this condition, with a phase 3 study underway. The FDA grants BTD to expedite development of medicines for serious conditions with substantial improvement potential.
Nasal Drug Delivery Technology Market Breakthrough in Patient Care, Projected ...
The Nasal Drug Delivery Technology Market is projected to grow from USD 4.4 billion in 2024 to USD 7.8 billion by 2031, driven by non-invasive drug administration, technological advancements, and rising respiratory disease prevalence.
Life Sciences M&A Trends For 2023 And 2024 (Through End Of Q3) In Greater China
Goodwin's two-part series on Greater China's life sciences sector highlights stable M&A activity in pharmaceuticals/biotech despite market fluctuations. Notable 2024 deals include Fosun's $1.71B acquisition of Shanghai Henlius Biotech, Johnson & Johnson's $850M purchase of Proteologix, and Novartis' acquisition of SanReno Therapeutics. Trends indicate a shift towards CAR-T cell therapies and large molecule/biologics, with medical devices also gaining significance. Factors driving recovery include regulatory changes, market readjustments, and the maturing of early-stage investments.
Earnings call: Legend Biotech sees robust growth in CARVYKTI sales
Legend Biotech reports 87.6% YOY growth in CARVYKTI sales, reaching $286 million, despite a $125 million net loss due to foreign exchange losses. The company maintains financial stability with $1.2 billion in cash reserves, projecting operational funding into 2026. Key highlights include CARVYKTI's 45% reduction in death risk for multiple myeloma patients, expansion in Europe and the U.S., and the appointment of Alan Bash as President of the CARVYKTI business unit. The company anticipates sequential revenue growth in Q4 2024 and plans to submit overall survival data to the FDA and EMA for potential label updates by end of next year.
Boston Scientific resumes PFA trial in new patient group after pausing enrollment
Boston Scientific resumes Avant Guard trial of pulsed field ablation (PFA) for persistent atrial fibrillation (AFib), comparing PFA against anti-arrhythmic drugs. Farapulse PFA system, FDA-approved for paroxysmal AFib, is being evaluated for persistent AFib. The trial's pause was to assess unanticipated observations, which did not affect confidence in Farapulse's performance.
Johnson & Johnson wins FDA IDE for Ottava surgical robot
Johnson & Johnson MedTech received FDA IDE for its Ottava surgical robot, allowing initiation of a U.S. clinical trial. The platform, unveiled in 2020, features four robotic arms integrated into a standard surgical table, designed to enhance surgical workflows and patient care.
J&J's Ottava surgical robot to begin clinical trial after FDA nod
Johnson & Johnson received FDA IDE approval for its Ottava surgical robot, aiming to compete with Intuitive Surgical's da Vinci system. Ottava will use J&J Ethicon instruments and feature a digital system, Polyphonic, to connect technologies and support clinical decisions. The robot's design addresses unmet needs in robotic surgery, promoting competition in the high-growth market.
FDA grants breakthrough therapy designation to nipocalimab for Sjögren's disease
FDA grants breakthrough therapy designation to nipocalimab for treating moderate to severe Sjögren’s disease, marking the first such designation for the condition.
Nasal Drug Delivery Technology Market Breakthrough in Patient Care
The Nasal Drug Delivery Technology Market is projected to grow from USD 4.4 billion in 2024 to USD 7.8 billion by 2031, driven by non-invasive drug administration, technological advancements, and rising respiratory disease prevalence.
© Copyright 2024. All Rights Reserved by MedPath